Recombinant Mouse CCL5/RANTES Protein, CF Summary
Details of Functionality |
Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CCR5. The ED50 for this effect is 1.5‑9 ng/mL. Measured by its ability to chemoattract 2-day cultured human monocytes. The ED50 for this effect is 30‑100 ng/mL. |
Source |
E. coli-derived mouse CCL5/RANTES protein Ser24-Ser91 |
Accession # |
|
N-terminal Sequence |
Ser24 |
Protein/Peptide Type |
Recombinant Proteins |
Gene |
Ccl5 |
Purity |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
Endotoxin Note |
<0.01 EU per 1 μg of the protein by the LAL method. |
Applications/Dilutions
Dilutions |
|
Theoretical MW |
7.9 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
Publications |
Read Publications using 478-MR/CF in the following applications:
|
|
Packaging, Storage & Formulations
Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
|
Buffer |
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with Trehalose. |
Purity |
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
Reconstitution Instructions |
Reconstitute at 100 μg/mL in sterile PBS. |
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Mouse CCL5/RANTES Protein, CF
Background
CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta -chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1 - 3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature mouse CCL5 shares 100% aa sequence identity with rat CCL5 and 75% - 88% with canine, cotton rat, feline, and human CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11 - 13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14 - 16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).
- Schall, T.J. et al. (1990) Nature 347:669.
- Bacon, K.B. et al. (1995) Science 269:1727.
- Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
- Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
- Heeger, P. et al. (1992) Kidney Int. 41:220.
- Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
- Levy, J.A. (2009) J. Immunol. 182:3945.
- Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
- DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
- Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
- Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
- Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
- von Hundelshausen, P. et al. (2005) Blood 105:924.
- von Hundelshausen, P. et al. (2001) Circulation 103:1772.
- Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
- Baltus, T. et al. (2003) Blood 102:1985.
- Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.
Customers Who Viewed This Item Also Viewed...
Species: Hu
Applications: ELISA
Species: Hu
Applications: BA
Species: Mu
Applications: ELISA
Species: Hu
Applications: ELISA
Species: Hu
Applications: CyTOF-ready, Flow, ICC, Neut
Species: Hu
Applications: CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta), ICC, ICFlow, Neut, Simple Western, WB
Species: Mu
Applications: ELISA
Species: Mu
Applications: ELISA
Species: Hu
Applications: BA
Species: Hu
Applications: BA
Species: Mu
Applications: ELISA
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Hu
Applications: CyTOF-ready, Flow
Species: Hu
Applications: BA
Species: Mu
Applications: ELISA
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), Neut
Species: Hu, Rb, Rt
Applications: Flow, IHC, IHC-P, KO, WB
Species: Hu
Applications: ELISA
FAQs for CCL5/RANTES (478-MR/CF) (0)
Additional CCL5/RANTES Products
Blogs on CCL5/RANTES